Ward M P, Ibrahim E M, O'Toole S A, Marchocki Z, O'Leary J J, Saadeh F Abu, Norris L A
Trinity St. James's Cancer Institute, Dublin, Ireland; Dept Of Histopathology, Trinity College Dublin, Ireland.
Department of Obstetrics and Gynaecology, Trinity College Dublin, Dublin, Ireland; Division of Gynae-oncology, Trinity St. James's Cancer Institute, Dublin, Ireland; Trinity St. James's Cancer Institute, Dublin, Ireland.
Thromb Res. 2025 Feb;246:109251. doi: 10.1016/j.thromres.2024.109251. Epub 2024 Dec 30.
Tumour type, treatment and patient related factors contribute to cancer associated venous thromboembolism (VTE), however, the role of each factor and the mechanisms involved are not understood.
To assess the role of the tumour, and of chemotherapy, in mediating the procoagulant response associated with VTE in gynaecological cancer patients.
Gynaecological cancer patients who developed VTE during follow-up (n = 59) (VTE+) were matched with treatment naïve(treatment (-)(VTE-)(n = 120) and chemotherapy treated patients(treatment (+)(VTE-) (n = 57)). Thrombin generation, Factor V(FV), VIIIc(FVIIIc), Tissue Factor Pathway Inhibitor(TFPI), soluble Thrombomodulin(sTM), Protein S(PS), C(PC) endothelial protein C receptor(EPCR) and fibrinogen were compared in each group. EPCR and TM expression was assessed in EA.hy926 cells in vitro following addition of chemotherapy agents. mRNA expression of coagulation genes was measured in tumour biopsies.
Thrombin generation was increased in treatment(-)VTE(+) compared with treatment(-)VTE(-) controls but not in the treatment(+)VTE(+) patients. Using the TM modified assay, thrombin generation was increased in the treatment (+)VTE(-) group compared with treatment(-)(VTE-) with a further increase in the treatment (+) VTE(+) group. Reduced levels of sTM in treatment (+) VTE(+) patients correlated with thrombin generation. TM expression was reduced in vitro by carboplatin and paclitaxel. FVIIIc was increased in both VTE groups and was predictive of VTE. F5 mRNA levels were lower in tumours from VTE(+) patients compared with controls.
Chemotherapy alters sTM and confers an acquired activated Protein C(aPC) resistance which may be implicated in cancer associated VTE in gynaecological cancer patients. FVIIIc may be a useful predictive marker for VTE in cancer patients in this setting.
肿瘤类型、治疗方法及患者相关因素均与癌症相关静脉血栓栓塞症(VTE)有关,但各因素的作用及相关机制尚不清楚。
评估肿瘤及化疗在介导妇科癌症患者VTE相关促凝反应中的作用。
将随访期间发生VTE的妇科癌症患者(n = 59)(VTE+)与未接受治疗的患者(治疗(-)(VTE-)(n = 120))及接受化疗的患者(治疗(+)(VTE-)(n = 57))进行匹配。比较各组的凝血酶生成、因子V(FV)、VIIIc(FVIIIc)、组织因子途径抑制物(TFPI)、可溶性血栓调节蛋白(sTM)、蛋白S(PS)、蛋白C(PC)、内皮蛋白C受体(EPCR)和纤维蛋白原。在体外添加化疗药物后,评估EA.hy926细胞中EPCR和TM的表达。在肿瘤活检组织中检测凝血基因的mRNA表达。
与治疗(-)VTE(-)对照组相比,治疗(-)VTE(+)组的凝血酶生成增加,但治疗(+)VTE(+)患者中未增加。使用TM改良检测法,治疗(+)VTE(-)组的凝血酶生成比治疗(-)(VTE-)组增加,治疗(+)VTE(+)组进一步增加。治疗(+)VTE(+)患者中sTM水平降低与凝血酶生成相关。在体外,卡铂和紫杉醇可降低TM表达。两个VTE组的FVIIIc均升高,且可预测VTE。与对照组相比,VTE(+)患者肿瘤中的F5 mRNA水平较低。
化疗可改变sTM并导致获得性活化蛋白C(aPC)抵抗,这可能与妇科癌症患者的癌症相关VTE有关。在这种情况下,FVIIIc可能是癌症患者VTE的有用预测标志物。